⁹⁰Yttrium-hydroxyapatite: a new therapeutic option for radioactive synovectomy in haemophilic synovitis.
| Autor: | Thomas S; Nuclear Medicine Service, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. sylviahemato@gmail.com, Gabriel MC, de Souza SA, Gomes SC, Assi PE, Pinheiro Perri ML, Liberato W, Matushita CS, Gutfilen B, da Fonseca LM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2011 Sep; Vol. 17 (5), pp. e985-9. Date of Electronic Publication: 2011 Mar 09. |
| DOI: | 10.1111/j.1365-2516.2011.02497.x |
| Abstrakt: | Recurrent haemarthroses often lead to chronic synovitis in patients with haemophilia and von Willebrand disease. Radioactive synovectomy with yttrium-90 (⁹⁰Y) citrate is frequently used to treat this complication, usually with good results. Since 2006, the Nuclear Energy Research Institute (IPEN, Sao Paulo, Brazil) has produced hydroxyapatite particles labelled with ⁹⁰Y for radioactive synovectomy. The aim of this study was to compare the results achieved by both forms of ⁹⁰Y in the treatment of haemophilic synovitis. We included 221 joints from 136 patients (age range: 6-20 years), treated by one of the two radiopharmaceuticals, at the Hemocenter of Mato Grosso, Brazil. The outcomes analysed were the annual frequency of haemarthrosis, articular pain and joint range of motion before and 1 year after RS. Similar results were achieved regardless of whether ⁹⁰Y hydroxyapatite or ⁹⁰Y citrate was used, and results were independent of the joint type, age, gender, radiologic stage and presence of inhibitors. ⁹⁰Y hydroxyapatite appears to be equivalent to the reference product ⁹⁰Y citrate in the treatment of chronic synovitis associated with bleeding disorders. (© 2011 Blackwell Publishing Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|